Zimmer has stated, Biologics are a priority for them.
Elongate synthetic collagen fiber to induce cells to differentiate into a specific tissue type i.e. tendon, ligament or maybe muscle. These patents will make mdxg much more valuable and sought after by suitors wanting a biologic stem cell company.
Each Mimedx investor should call them and spend 30 minutes just chatting. These ambulance chasers seem to have extra time on their hands.
Agree with Earth, Suraj and his shorts are desperate. They will get a lot more desperate over the next month.
I appreciate your enthusiasm, but please keep your posts factual. I use this product and wound healing is remarkable and revenues will start to accelerate starting this quarter reporting end April. Many new surgical applications coming on line. Buy and hold til buyout and you will be happy.
For his role in Herbalife short while lodging a suspect public campaign against the company. It's about time someone went after these crooks who use public, legal, journalist and government entities to manipulates stock.
this is another significant milestone for this stem cell biologics company. These antic cancer/ anti fungal/ anti microbial will enhance Mimedx value and broaden the list of potential suitors. Very $trong
Companies want Mimedx now, but Pete isn't selling for $10-15 per share. Zimmer has biologics as a PRIORITY and there will be multiple bidders. Pete will likely wait for 2016 revenues of 300 million to 400 million to entertain serious offers.
So, it's anything to attack Mimedx. He upgrades the competition and downgrades Mimedx. His work is lackadaisical and looks like grade school work.
There are multiple surgical applications that will develop over 2015-16. Additionally the is another field that could match 2014 revenue over 3015-16. We are talking 200 million in 2015 and 400 million in 2016 if these new areas develop as I suspect. Then we have the wild card injectable for 2016 and after. It is difficult to put a pps on a stock with enormous growth and one which will be a hot takeover target. Whatever, you think it may be higher and you have to ask yourself should I buy more now.
SGA doesn't matter to whomever is buying mdxg. They have multiple patents for vascular shields, anti-fungal, cancer treatment regimens etc. These will also be important to whomever is buying mdxg. By the way you were up late posting on mdxg message board and again early this morning. Are you panicking?
A couple surgical applications and possibly dental could push us over 200 million for 2014. They can have a better view in 3 months.